Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto

Patent metadata

Field	Value
Publication number	US-2020375930-A1
Application number	US-202016848746-A
Country	US
Kind code	A1
Filing date	Apr 14, 2020
Priority date	Mar 18, 2008
Publication date	Dec 3, 2020
Grant date	—

Abstract

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

First claim

1 .- 72 . (canceled)

73 . A process for the preparation of a compound of Formula (III):

or a salt form thereof,
wherein:
R 1 is selected from C 1 -C 6 alkyl, aryl and heteroaryl; each optionally substituted with one or two substituents selected from: C 1 -C 6 alkoxy, C 1 -C 6 alkyl, aryl, C 1 -C 6 haloalkoxy, C 1 -C 6 haloalkyl and halogen;
R 2 is selected from: H, C 1 -C 6 alkyl and aryl; wherein said aryl is optionally substituted with one or two substituents selected from: C 1 -C 6 alkyl and halogen; and
R 5 is C 1 -C 6 alkyl;

comprising reacting a compound of Formula (IV):

or a salt from thereof, with a compound of Formula (V):

wherein:
R 6 is selected from: C 1 -C 6 alkylarylsulfonate, C 1 -C 6 alkylsulfonate, arylsulfonate, C 1 -C 6 haloalkylsulfonate and halogen;
in the presence of a base to form a compound of Formula (III) or a salt form thereof.

74 . The process of claim 73 , wherein the R 1 is aryl, optionally substituted with one or two substituents selected from: C 1 -C 6 alkoxy, C 1 -C 6 alkyl, aryl, C 1 -C 6 haloalkoxy, C 1 -C 6 haloalkyl and halogen.

75 . The process of claim 73 , wherein the R 2 is aryl optionally substituted with one or two substituents selected from: C 1 -C 6 alkyl and halogen.

76 . The process of claim 73 , wherein the R 5 is tert-butyl.

77 . The process of claim 73 , wherein the R 6 is halogen.

Assignees

• Arena Pharm Inc

Inventors

• Tran Thuy-Anh
• Chen Weichao
• Kramer Bryan A
• Sadeque Abu J M
• Shifrina Anna
• Shin Young-Jun
• Vallar Pureza
• Zou Ning

Classifications

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K31/44

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title